A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ESAs / erythropoiesis-stimulating agents

[Related PubMed/MEDLINE]
Total Number of Papers: 814
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ESAs  (>> Co-occurring Abbreviation)
Long Form:   erythropoiesis-stimulating agents
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Novel Choice to Correct Inflammation-Induced Anemia in CKD: Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat. CKD, EPO
2020 A recurrent neural network approach to predicting hemoglobin trajectories in patients with End-Stage Renal Disease. ESRD, Hgb
2020 Anemia management in dialysis patients: a PIVOT and a new path? EPO, HIF-PHIs
2020 Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient. C.E.R.A, PRCA
2020 Are all erythropoiesis-stimulating agents created equal? EPO, Hb, PHD
2020 Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease? CVD, EPO, PHD
2020 Biomarkers of iron metabolism in chronic kidney disease. ERFE, ESRD
2020 Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. ---
2020 Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. ---
10  2020 Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review. CKD, CV, HIF-PHI
11  2020 Development of a clinical prediction tool for cancer-associated venous thromboembolism (CAT): the MD Anderson Cancer Center CAT model. CAT
12  2020 Direct healthcare costs of chronic kidney disease management in Italy: what cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents? CKD
13  2020 Early erythropoiesis-stimulating agents in preterm or low birth weight infants. CENTRAL, CI, CINAHL, EPO, IVH, MDI, NEC, NNTB, PVL, RBC, RD, ROP, RR, WMD
14  2020 Early responsiveness to continuous erythropoietin receptor activator predicts renal prognosis and is determined by a novel antioxidative marker in non-dialysis chronic kidney disease: a prospective, observational, single-center study. BAP, CERA, CKD, Hb
15  2020 Effect of Erythropoiesis Stimulating Agents on Clinical Outcomes in Breast Cancer Patients: A Systematic Review of Randomised Controlled Trials. DA, EA, EB, QOL, RCTs, TEEs
16  2020 Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. CKD, Hb CFB, HIF-PHIs, RCTs
17  2020 Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia. BP, CERA, DA, Hb
18  2020 Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. ---
19  2020 End of an era for erythropoiesis-stimulating agents in oncology. CIA
20  2020 Enhanced prediction of hemoglobin concentration in a very large cohort of hemodialysis patients by means of deep recurrent neural networks. ESRD, RNNs
21  2020 Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. ERFE
22  2020 Erythropoietin induces miRNA-210 by JAK2/STAT5 signaling in PBMCs of End-stage Renal Disease patients. EPO, ERI, HC, HD, JAK2, STAT5
23  2020 Erythropoietin production by the kidney and the liver in response to severe hypoxia evaluated by Western blotting with deglycosylation. EPO, LC/MS
24  2020 Erythropoietin stimulating agents as replacement therapy for blood transfusions in critically ill patients with anaemia: A systematic review with meta-analysis. CI, Hb, ICU, RBC, RR
25  2020 Erythropoietin Treatment Is Associated with Decreased Blood Glucose Levels in Hematologic Patients. MDS, MM
26  2020 Glycan analysis of erythropoiesis-stimulating agents. ---
27  2020 How I treat anemia in heart failure. HF, ID
28  2020 How I treat cancer-associated anemia. ---
29  2020 Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease? CKD, EPO, HIF-PH, HIF-PHIs
30  2020 In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study. CKD
31  2020 Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. CKD, DA, Hb, iEResI
32  2020 Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. CKD, ESA, ESA, Hb, PD, TEAEs
33  2020 Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. CI, EPO, MD, NNTB, RBC, RD, ROP, RR
34  2020 Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. CKD, HD, Hgb
35  2020 Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial. ERI, HD, MCO
36  2020 Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: a prospective randomized study. HD, Mixed HDF, Post-HDF
37  2020 Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years. MDS
38  2020 Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. CKD, PCOs, PROMs, QOL
39  2020 Perioperative Anemia: Prevention, Diagnosis, and Management Throughout the Spectrum of Perioperative Care. ---
40  2020 Population Pharmacodynamic Modeling of Epoetin Alfa in End-Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach. Hgb
41  2020 Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). CKD, J-CKD-DB
42  2020 Prolonged Duration of Erythropoiesis-Stimulating Agents' Action Delays Disease Progression in Anti-Thy 1 Antibody-Induced Chronic Glomerulonephritis Rats. EPO, GN, Hb, UTP
43  2020 Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. CIA
44  2020 Relationship between anti-erythropoietin receptor autoantibodies and responsiveness to erythropoiesis-stimulating agents in patients on hemodialysis: a multi-center cross-sectional study. CRP, EpoR, ERI
45  2020 Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies and cancer: perspectives with opinion and commentary. RCTs
46  2020 Role of nephrology pharmacists in the management of anemia in outpatient dialysis units: A Canadian model
. ---
47  2020 Screening and confirmatory analysis of recombinant human erythropoietin for racing camels' doping control. rHuEPO
48  2020 The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion. MDS, sEPO
49  2020 Treating anaemia in patients with chronic kidney disease: what evidence for using ESAs, after a 30-year journey? ---
50  2020 Treatment of Renal Anemia with Roxadustat: Advantages and Achievement. CKD, EPO, Hb, HIF, PHD
51  2020 Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease. CI, CKD, ESKD, HR
52  2020 Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach. EPO
53  2019 A simple method to immunopurify erthyropoiesis stimulating agents from urine, aiming to optimize erythropoietin screening by SAR-PAGE. ELISA, EPGK, EPK, EPO, LOD
54  2019 Anemia Management Considering the Pathophysiology of Elderly Chronic Kidney Disease Patients. CKD, Hb
55  2019 Anemia management in cancer patients with chronic kidney disease. ---
56  2019 Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. MDS, QOL
57  2019 Combined immuno-purification and detection of recombinant erythropoietins and activin receptor type II-Fc fusion proteins by isoelectric focusing for application in doping control. ActRII-Fc, IEF, rEPOs, WADA
58  2019 Different Effects of Iron Indices on Mortality in Patients With Autosomal Dominant Polycystic Kidney Disease After Long-Term Hemodialysis: A Nationwide Population-Based Study. HRs, PKD, TSAT
59  2019 Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. CKD, DD, Hb, HRQoL, HRU, SLR
60  2019 Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. CKD, HRQoL, HRU, NDD
61  2019 Economic Evaluation of Ferric Carboxymaltose for the Management of Hemodialysis Patients with Iron Deficiency Anemia in Italy. FCM, FG, Hb, HD, IDA
62  2019 Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients. Hb, Mixed-HDF, Post-HDF
63  2019 Efficacy and safety of erythropoietin and iron therapy to reduce red blood cell transfusion in surgical patients: a systematic review and meta-analysis. CI, DVT, MI, PE, RBC, RR
64  2019 Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma. CIA, NHL
65  2019 Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols. MDS
66  2019 Erythropoietin inhibits chemotherapy-induced cell death and promotes a senescence-like state in leukemia cells. EPO, EpoRs, ncRNAs
67  2019 Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients. CKD, Hb, iPTH
68  2019 Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. MDS, VTE
69  2019 Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients. ERI, Hb, HD, hs-CRP, IL-6
70  2019 In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. CKD, Hb, LHUs, ROC
71  2019 International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Hb, PD, PDOPPS, TSAT, UK, US
72  2019 Iron Metabolism in Chronic Kidney Disease Patients. CKD, EPO
73  2019 Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease. CKD, TIBC, TSAT
74  2019 Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants. CI, EPO, MD, NNTB, RBC, RD, ROP, RR
75  2019 Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. ASCO, ASH, RCTs
76  2019 Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. ASCO, ASH, RCTs
77  2019 Misdistribution of iron and oxidative stress in chronic kidney disease. CKD, CVD
78  2019 Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. CKD, HD-C, HD-M, MIYABI, PD
79  2019 Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. CKD, Hb, HIF-PH, MIYABI, ND-C, ND-M
80  2019 Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. CKD, TEAEs
81  2019 Parenteral versus oral iron therapy for adults and children with chronic kidney disease. CI, CKD, MD, RCTs, RR, SMD
82  2019 Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation. DcytB, DMT1, EPO, LPS, MCP-1, RBC, WBC
83  2019 Regional variance in patterns of prescriptions for chronic kidney disease in Japan. CKD, PBs
84  2019 Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis. ICU, RCTs, RR
85  2019 Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes. MDS
86  2019 Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease: A retrospective study in Beijing, China. CKD
87  2019 The effects of erythropoiesis-stimulating agents on the management of chemotherapy-induced anemia and tumor growth in diffuse large B-cell lymphoma patients. ABC, CDC, DLBCL, EPO, EPOR, GCB, R-CHOP
88  2019 The Evolution of Target Hemoglobin Levels in Anemia of Chronic Kidney Disease. ---
89  2019 The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. CRA, FID
90  2019 The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach. CKD, Hb
91  2019 Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study. CERA, CKD, ESA, HCP
92  2019 Transforming growth factor (TGF)-beta pathway as a therapeutic target in lower risk myelodysplastic syndromes. LR, MDS, TGF
93  2019 Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies. HRQoL, MDS, RBC
94  2019 Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Hb, KDCPMS, TSAT
95  2019 Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. ---
96  2019 Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection. ---
97  2018 A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. CIA, CKD-IA, HRQoL, SLRs
98  2018 Activin receptor ligand traps in chronic kidney disease. ActRII, TGF-ss
99  2018 Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. ID, PBM, TSAT
100  2018 Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. CKD